The primary objective of the Hawaii Minority-Based Community Clinical Oncology (MBCCOP) is to build on its past 15 year success in providing National Cancer Institute (NCI) clinical trials to Hawaii cancer patients and high risk individuals in order to reduce cancer incidence, morbidity and mortality by: 1. providing support to expand clinical research in the State of Hawaii, a multiethnic population with a majority of ethnic minority patients;2. bringing the advantages of state-of-the-science treatment and prevention/control research to minority individuals in their own communities;3. facilitating broader participation among underserved populations in NCI-approved research;4. strengthening the operational base that presently exists to extend cancer prevention and control research in the population;5. increasing the involvement of primary health care providers and other specialists in cancer treatment, prevention, and control studies. The Cancer Research Center of Hawaii will serve as the administrative headquarters for the MBCCOP and will direct recruitment, accrual, and data management for NCI-approved cancer treatment, prevention and symptom control clinical trials. Sources of clinical trials include: SWOG, GOG, COG, RTOG, URCC, CTSU, and NSABP prevention trials. Participating physicians include oncologists on Oahu, Kauai, Maui, and the Big Island of Hawaii as well as professionals from other medical and non-medical specialties. All major hospitals in the state will serve as component/affiliate institutions. The MBCCOP will allow the people of Hawaii, about 75% who are ethnic minorities, to benefit from access to state-of-the-science cancer treatment, prevention and symptom control studies while providing valuable clinical research data on a unique population.

Public Health Relevance

Provide access to NCI-approved cancer treatment, prevention and control clinical trials for the people of Hawaii especially for minorities and under-served populations. Lower the burden of cancer in the State of Hawaii. Provide data on differences in cancer incidence, morbidity, mortality and treatment effects as a function of ethnicity, gender, and age.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA063844-19
Application #
8329651
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
1994-08-01
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
19
Fiscal Year
2012
Total Cost
$543,533
Indirect Cost
$213,929
Name
University of Hawaii
Department
Type
Organized Research Units
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
El-Khoueiry, A B; Rankin, C; Siegel, A B et al. (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882-7
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Malhotra, Binu; Moon, James; Kucuk, Omar et al. (2014) Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 36:1712-7
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Sha, Dan; Lee, Adam M; Shi, Qian et al. (2014) Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res 20:3319-27

Showing the most recent 10 out of 113 publications